

**Special isirv-AVG Virtual Conference on
'Therapeutics for COVID-19'**

Tuesday 6th - Thursday 8th October 2020 (12.00-16.00 GMT daily)

Preliminary Programme

Tuesday 6 October	
12:00-12:15	<p>Welcome Alan Hay, Francis Crick Institute, London, UK & Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA</p> <p>Opening Remarks Jeremy Farrar, Wellcome Trust, London, UK</p>
12:15-12:40	<p>Co-Chairs: TBC</p> <p>COVID-19 Clinical Spectrum, Complications, and Coinfections <i>Bin Cao, China-Japan Friendship Hospital, Beijing, China</i></p>
12:40-13:00	<p>Viral Replication Kinetics and Antibody Responses <i>Malik Peiris, University of Hong Kong, HK SAR, China</i></p>
13:00-13:20	<p>COVID-19 Autopsy Findings <i>Xiuwu Bian, Third Military Medical University, Chongqing, China</i></p>
13:20-13:40	<p>Immunopathogenesis of COVID-19 <i>Peter Openshaw, Imperial College London, UK</i></p>
13:40-14:00	<p>Pathogenesis and Management of ARDS – <i>Richard Wunderink, Northwestern University, Evanston, IL, USA</i></p>
14:00-14:10	Comfort Break
14:10-15:10	<p>Co-Chairs: TBC</p> <p>Oral Abstract Session 1 4 x 15 minute presentations (including Q&A)</p>
15:10-15:20	<p>Close of Day 1 Poster Viewing</p>

Wednesday 7 October	
<p>12:00-12:20</p> <p>12:20-12:40</p> <p>12:40-13:10</p> <p>13:10-13:30</p> <p>13:30-13:50</p>	<p>Co-Chairs: TBC</p> <p>SARS-CoV-2 Antiviral Targets <i>Mark Denison, Vanderbilt University Medical Center, Nashville, TN, USA</i></p> <p>Pre-clinical Models for Downselecting Candidates <i>Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France</i></p> <p>RECOVERY Trial and Strategies for Rapid Clinical Testing <i>Peter Horby, University of Oxford, Oxford, UK</i></p> <p>Convalescent Plasma and Polyclonal Antibodies - <i>Michael Joyner, Mayo Clinic, Rochester, MN, USA</i></p> <p>Monoclonal Antibodies <i>Erica Saphire, La Jolla Institute for Immunology, CA, USA</i></p>
13:50-14:00	Comfort Break
14:00-15:00	<p>Co-Chairs: TBC</p> <p>Oral Abstract Session 2</p> <p>4 x 15 minute presentations (including Q&A)</p>
15:00-15:15	Close of Day 2
	Poster Viewing

Thursday 8 October	
12:00-12:20 12:20-12:45	<p>Co-Chairs: TBC</p> <p>Lessons from MERS – <i>Yaseen Arabi, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia</i></p> <p>Solidarity Trial & Lessons Learned – <i>Ana Maria Henao-Restrepo, WHO, Geneva, Switzerland (TBC)</i></p>
12:45-14:15	<p>Co-Chairs: TBC</p> <p>Clinical Trials Updates (15 minute presentations including Q&A)</p> <p>Remdesivir - <i>Anu Osinusi, Gilead, Foster City, CA, USA</i> EIDD-2801 - <i>Wendy Painter, Ridgeback Biotherapeutics LP, Miami, FL, USA</i> Favipirivir – <i>Yohei Doi, University of Pittsburgh, PA, USA</i> JAK Inhibitors - <i>John Beigel, NIAID, Bethesda, MD, USA</i> Tocilizumab – <i>Larry Tsai, Genentech, South San Francisco, CA, USA</i></p>
14:15-14:25	<p>Comfort Break</p>
14:25-14:45 14:45-15:00 15:00-15:30	<p>Co-Chairs: TBC</p> <p>Operation Warp Speed Therapeutics Development - <i>Janet Woodcock, CDER, FDA, Washington DC, USA</i></p> <p>Discussion on Clinical Trial Endpoints – <i>moderated by Michael Ison, Northwestern University, Evanston, IL, USA & Marco Cavaleri, European Medicines Agency, Amsterdam, Netherlands</i></p> <p>WHO Update on COVID-19 Clinical Management – <i>Janet Diaz, WHO, Geneva, Switzerland</i></p>
15:30-15:45	<p>Summary and Close of Conference</p>